CA2524485A1 - Vaccinating against infectious diseases using proteosomes - Google Patents

Vaccinating against infectious diseases using proteosomes Download PDF

Info

Publication number
CA2524485A1
CA2524485A1 CA002524485A CA2524485A CA2524485A1 CA 2524485 A1 CA2524485 A1 CA 2524485A1 CA 002524485 A CA002524485 A CA 002524485A CA 2524485 A CA2524485 A CA 2524485A CA 2524485 A1 CA2524485 A1 CA 2524485A1
Authority
CA
Canada
Prior art keywords
antigen
proteosomes
immunogenic composition
liposaccharide
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002524485A
Other languages
English (en)
French (fr)
Inventor
David Hugh Jones
David S. Burt
George H. Lowell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
Id Biomedical Corporation Of Quebec
David Hugh Jones
David S. Burt
George H. Lowell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corporation Of Quebec, David Hugh Jones, David S. Burt, George H. Lowell filed Critical Id Biomedical Corporation Of Quebec
Publication of CA2524485A1 publication Critical patent/CA2524485A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002524485A 2003-05-05 2004-05-05 Vaccinating against infectious diseases using proteosomes Abandoned CA2524485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46762403P 2003-05-05 2003-05-05
US60/467,624 2003-05-05
PCT/US2004/014236 WO2004098636A2 (en) 2003-05-05 2004-05-05 Vaccinating against infectious diseases using proteosomes

Publications (1)

Publication Number Publication Date
CA2524485A1 true CA2524485A1 (en) 2004-11-18

Family

ID=33435094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002524485A Abandoned CA2524485A1 (en) 2003-05-05 2004-05-05 Vaccinating against infectious diseases using proteosomes

Country Status (5)

Country Link
EP (1) EP1622641A2 (ja)
JP (1) JP2006525373A (ja)
AU (1) AU2004235815A1 (ja)
CA (1) CA2524485A1 (ja)
WO (1) WO2004098636A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255867B2 (en) 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
ES2615169T3 (es) 2003-10-22 2017-06-05 Id Biomedical Corporation Of Quebec Composiciones y procedimientos de activación de la inmunidad innata y alérgica
EP2068834A2 (en) * 2006-09-08 2009-06-17 Becton, Dickinson & Company Stable powder formulations of aluma-dsorbed vaccines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1244687A4 (en) * 1999-12-22 2005-06-15 Univ Ohio State Res Found METHODS OF PROTECTION AGAINST LETHAL INFECTION BY BACILLUS ANTHRACIS / i
JP4137640B2 (ja) * 2001-03-09 2008-08-20 アイディー バイオメディカル コーポレイション オブ ケベック 新規プロテオソーム−リポサッカリドワクチンアジュバント

Also Published As

Publication number Publication date
EP1622641A2 (en) 2006-02-08
WO2004098636A8 (en) 2005-08-18
AU2004235815A1 (en) 2004-11-18
WO2004098636A2 (en) 2004-11-18
WO2004098636A3 (en) 2005-05-19
JP2006525373A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
EP2114444B1 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US20130089570A1 (en) Oral vaccine compromising an antigen and a toll-like receptor agonist
US8709447B2 (en) Compositions and methods for activating innate and allergic immunity
Dabo et al. Vaccination with Pasteurella multocida recombinant OmpA induces strong but non-protective and deleterious Th2-type immune response in mice
WO2014064229A1 (en) Nicotinamide as adjuvant
EP1954307A2 (en) Salmonella based oral vaccines for anthrax
Karam et al. Use of flagellin and cholera toxin as adjuvants in intranasal vaccination of mice to enhance protective immune responses against uropathogenic Escherichia coli antigens
Habibi et al. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model
US20110256214A1 (en) Single-time vaccines
CA2627364A1 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US10293041B2 (en) Multivalent stable vaccine composition and methods of making same
CA2524485A1 (en) Vaccinating against infectious diseases using proteosomes
JP2004508424A (ja) 免疫調節調剤物
WO2000023107A1 (fr) Preparations de vaccin contenant des toxines attenuees
US20140242112A1 (en) Novel vaccine
Mirchamsy et al. Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections
Lowell et al. Proteosome™ technology for vaccines and adjuvants
Croia Analysis and optimization of immune responses elicited by Outer Membrane Vesicles (OMVs)

Legal Events

Date Code Title Description
FZDE Dead